221 filings
Page 5 of 12
424B5
wecaniehhu9kop
8 Sep 20
Prospectus supplement for primary offering
4:42pm
8-K
ptu3rmc6
8 Sep 20
Athenex’s oral paclitaxel plus encequidar is being evaluated in combination with GSK’s dostarlimab in the neoadjuvant chemotherapy setting
9:16am
S-8
jwn500zzezi6ddw
6 Aug 20
Registration of securities for employees
4:32pm
S-3ASR
doae62y8hmugr1v
6 Aug 20
Automatic shelf registration
4:31pm
8-K
f640fe383j64z2t3pv
6 Aug 20
Entry into a Material Definitive Agreement
7:00am
8-K
epqclw 4qli6b7k4mfg
22 Jun 20
Entry into a Material Definitive Agreement
7:44am
8-K
yrmoxtx40t1t44
10 Jun 20
Departure of Directors or Certain Officers
12:00pm
CT ORDER
k7fs9ctfxmsukeau
14 May 20
Confidential treatment order
2:12pm
CT ORDER
m4g0aly2u2em1
13 May 20
Confidential treatment order
4:19pm
8-K
e4lowjkpbcc3b
7 May 20
Results of Operations and Financial Condition
7:03am
8-K
11bm2
30 Mar 20
Departure of Directors or Certain Officers
4:30pm
8-K
mj2l01 2ch4
27 Feb 20
Provides Corporate Update
7:31am
S-3ASR
3pc be62z
28 Jan 20
Automatic shelf registration
12:00am
8-K
7twyark49sdpz0s
16 Dec 19
Entry into a Material Definitive Agreement
7:01am
8-K
y6pnc6l tu6ubn
13 Dec 19
Regulation FD Disclosure
4:16pm
8-K
5voncvu1y0f9
13 Dec 19
Athenex Announces Superior Response and Survival with Lower Neuropathy of a Novel Oral
8:30am